5PSQ-058 Comparative effectiveness of regorafenib versus trifluridine/tipiracil in metastatic colorectal cancer

BACKGROUND: Regorafenib and trifluridine/tipiracil (TAS-102) are indicated in metastatic colorectal cancer (mCRC) refractary to standard therapies. Both have been approved after being compared to placebo, so comparative studies with other therapies are needed. PURPOSE: To compare effectiveness and s...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Hosp Pharm
Asıl Yazarlar: Arrieta, M, Lázaro, A, García, C, Rodríguez, P, Ortiz, S, Ferrari, JM
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2018
Konular:
Section 5: Patient safety and quality assurance
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535839/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.412
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller